Alzheimer's Disease Research Center

描述（由申请人提供）：本提案是为加州圣地亚哥大学阿尔茨海默病研究中心（ADRC）与巴克研究所合作进行的五年续约。未来五年，中心的主要目标将是扩大我们的努力，研究通过轻度认知障碍（MCI）的中间步骤从正常衰老到痴呆症的转化，并研究神经退行性疾病的机制。（Bondi，项目1），测试轴突紊乱在阿尔茨海默病中的作用（Goldstein，项目2），以及研究APP的胞质结构域及其在突触损伤中的相互作用蛋白（Koo，项目3）。该中心将继续保持非常强大的临床和神经病理学核心。临床核心将继续纵向表征约500名受试者的队列，以研究认知和语义记忆的早期变化，并为其他研究者和整个圣地亚哥社区提供高加索和西班牙裔志愿者的良好表征的临床队列。临床核心还将招募受试者和对照，以支持许多单个项目的特殊需求。该中心还将继续参与通过NACC或直接从NIA资助的与其他ADC的合作项目。受试者还将参加多中心药物试验。来自受试者的数据将用于合作研究。此外，我们将继续进行详细的临床病理相关性阿尔茨海默病和其他相关的神经退行性疾病：路易体变异的AD和额颞叶痴呆。神经病核心在这一奋进中发挥了主导作用。该中心作为一个整体将继续提供脑组织，血浆，血清，DNA和脑脊液研究者的要求。ADRC提供了一个环境，以促进研究人员的研究培训，并将通过我们的微型居住计划，会议和其他教育活动将信息传递给专业和非专业社区。数据管理和生物统计学 核心将继续为ADRC研究者提供统计设计和分析服务，准备提交给NACC的最低数据集，并协调临床和神经病理学核心生成的数据的录入、质量控制、管理和分析。

DESCRIPTION (provided by applicant): This proposal is for a five-year renewal of the Alzheimer's Disease Research Center (ADRC) at the University of California San Diego in consortium with The Buck Institute. The major goals of the Center over the next five years will be to expand our efforts into studying the conversion from normal aging to dementia through the intermediary step of Mild Cognitive Impairment (MCI) and to study mechanisms of neurodegeneration Projects will focus on functional MRI of the elderly at risk for Alzheimer's disease (Bondi, Project 1), testing of the role of axonal disturbances in Alzheimer's disease (Goldstein, Project 2), and studying the cytoplasmic domain of APP and its interacting proteins in synapse damage (Koo, Project 3). This Center will continue to maintain extremely strong Clinical and Neuropathological Cores. The Clinical Core will continue to longitudinally characterize a cohort of approximately 500 subjects to study early changes in cognition and semantic memory, and to provide other investigators and the San Diego community as a whole with a well characterized clinical cohort of both Caucasian and Hispanic volunteers. The Clinical Core will also recruit subjects and controls to support the special needs of many of the individual projects. The Center will also continue its participation in collaborative projects with other ADCs funded through the NACC or directly from NIA. Subjects will also participate in multi-center drug trials. Data derived from subjects will be used in collaborative research. In addition we will continue to carry out detailed clinicopathological correlations in Alzheimer's disease and other related neurodegenerative diseases: Lewy Body Variant of AD and fronto-temporal dementia. The Neuropath Core has taken a lead role in this endeavor. The Center as a whole will continue to provide brain tissue, plasma, serum, DNA, and cerebrospinal fluid to investigators upon request. The ADRC provides a setting to facilitate research training of investigators and will transfer information to the professional and lay communities through our miniresidency program, conferences and other educational activities. The Data Management and Biostatistics Core will continue to provide statistical design and analysis services to ADRC investigators, prepare the minimum data set for submission to the NACC, as well as coordinate the entry, quality control, management and analysis of data generated by the Clinical and Neuropathology Cores.